February 17, 2015 -
Imprivata has partnered with Symantec to provide a complete fingerprint biometric and FICAM-certified credential service provider (CSP) solution for the electronic prescribing of controlled substances (EPCS).
Symantec Norton Secure Login, which acts as the CSP, and Symantec Validation and ID Protection Services integrate with Imprivata Confirm ID to simplify the process of identity-proofing and authorizing prescribers to comply with DEA requirements for EPCS.
“Our strategic partnership with Symantec provides customers with a complete, DEA-compliant solution for identity-proofing individual prescribers to help meet regulatory requirements for EPCS,” said David Ting, CTO at Imprivata. “The integrated solution gives administrators a single workflow for enabling the use of Symantec one-time password tokens and/or Imprivata’s fingerprint biometric identification for EPCS. This gives hospitals greater flexibility in matching the best two-factor authentication option to fit their prescribers’ clinical workflow requirements.”
The DEA states that all individual prescribers must obtain two-factor authentication data from a GSA-approved CSP such as Symantec.
The combined Imprivata-Symantec solution gives providers a single solution for performing identity-proofing and credentialing tasks, enabling them to use OTP tokens and/or fingerprint biometric identification to fulfill two-factor authentication requirements for EPCS.
Imprivata Confirm ID offers identity-proofing, supervised enrollment of providers’ approved credentials, support for multiple DEA-approved two-factor authentication modalities for prescription signing, and a range of auditing and reporting tools.
The solution also simplifies EPCS by integrating directly into the e-prescribing workflows of EHRs and enabling providers to use the approved two-factor authentication credential options that meet their e-prescribing workflow requirements.
This ultimately improves efficiency and provider satisfaction while maintaining security, which greatly reduces the chance of fraud or drug diversion.